Therapeutic efficacy of FASN inhibition in preclinical models of HCC
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic efficacy of
FASN
inhibition in preclinical models of
HCC
Authors
Keywords
-
Journal
HEPATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-01-25
DOI
10.1002/hep.32359
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics
- (2021) Haichuan Wang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
- (2021) Rohit Loomba et al. GASTROENTEROLOGY
- Selective targeting of MYC mRNA by stabilized antisense oligonucleotides
- (2021) Taylor Gill et al. ONCOGENE
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Axin1 deletion induced hepatocarcinogenesis requires intact β-Catenin but not Notch cascade in mice
- (2019) Yu Qiao et al. HEPATOLOGY
- Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans
- (2019) Li Che et al. GUT
- Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
- (2019) Ying Zhang et al. Expert Opinion on Drug Metabolism & Toxicology
- Metabolic rearrangements in primary liver cancers: cause and consequences
- (2019) Letizia Satriano et al. Nature Reviews Gastroenterology & Hepatology
- β-catenin-activated hepatocellular carcinomas are addicted to fatty acids
- (2018) Nadia Senni et al. GUT
- Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins
- (2018) Maomao Zhang et al. Cancer Discovery
- Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer
- (2018) Yekaterina Y. Zaytseva et al. Oncotarget
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target
- (2017) Douglas Buckley et al. PHARMACOLOGY & THERAPEUTICS
- FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression
- (2017) Timothy S. Heuer et al. EBioMedicine
- The AMP analog AICAR modulates the Treg/Th17 axis through enhancement of fatty acid oxidation
- (2016) Guido A. Gualdoni et al. FASEB JOURNAL
- Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans
- (2016) Lei Li et al. JOURNAL OF HEPATOLOGY
- Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice
- (2016) Junjie Hu et al. Scientific Reports
- Fatty acid transport protein-2 inhibitor Grassofermata/CB5 protects cells against lipid accumulation and toxicity
- (2015) Nipun Saini et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis
- (2015) Pierre-Damien Denechaud et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression
- (2015) Richard Ventura et al. EBioMedicine
- Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
- (2014) Xin Chen et al. AMERICAN JOURNAL OF PATHOLOGY
- Met as a therapeutic target in HCC: Facts and hopes
- (2013) Silvia Giordano et al. JOURNAL OF HEPATOLOGY
- Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
- (2013) Matthias S. Matter et al. JOURNAL OF HEPATOLOGY
- AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2,
- (2011) Coral Ho et al. HEPATOLOGY
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation